Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

Inclusion Criteria: * have ocular health within normal limits. * have blood (hematology, blood chemistry) and urine analysis within normal limits. * have a body weight within 15% of ideal weight Exclusion Criteria: * have known contraindications or sensitivity to the use of any of the investigational drug(s) or their components, or any other medications required by the protocol; * have any active systemic or ocular disorder other than refractive disorder. * have presence of any abnormality of the lids, ocular surface, or lacrimal duct system that in the Investigator's opinion could affect ophthalmic drop absorption. * have a history of chronic alcohol consumption. * consume alcohol and/or caffeine or xanthine containing products within 48 hours prior to dosing at Visit 1 or anticipated use during the study. * have a history of tobacco, nicotine, or nicotine containing product use within the last year prior to Visit 2; * have significant weight change (over 10 pounds) within the 60 days prior to Visit 2; * have blood donation or equivalent blood loss of 450 ml or more, within 60 days prior to Visit 2; * have an abnormal blood pressure (defined as ≤ 90 or ≥ 160 (systolic) measured in mmHg or ≤ 60 or ≥ 100 (diastolic) measured in mmHg); * have intraocular pressure (IOP) that is less than 5 mmHg or greater than 22 mmHg or have a normal IOP with a diagnosis of glaucoma.